TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16899475
Drug: oral oestradiol‐17beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral oestradiol‐17beta 1 mg plus norethisterone acetate 0.5 mg daily
Study: 14976888
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of clomiphene and Chinese drugs for nourishing Shen and activating blood circulation (NSABC)
Study: 7636533
Drug: Acitretin 30
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin 30 mg/d for 6 months
Study: 31350938
Drug: Hochu-ekki-to (HET)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hochu-ekki-to (HET) 7.5 g oral per day, n = 9
Study: 28379607
Drug: Autologous skin
Normalized name: Autologous skin culture
DrugBank: Autologous skin culture (DB18524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous skin cell suspension plus hydrocolloid dressings
Study: 28379607
Drug: Autologous skin
Normalized name: Autologous skin culture
DrugBank: Autologous skin culture (DB18524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous skin cell suspension
Study: 21744377
Drug: Duloxetine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (mean 78.7 mg/day)
Study: 19760046
Drug: Traditional oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional oral feeding (TOF)
Study: 17893385
Drug: Self‐administered questionnaire
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐administered questionnaire
Study: 9215820
Drug: Droloxifene (DRO)
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene (DRO) as first-line hormone therapy (HT)
Study: 8459456
Drug: Piperacillin (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (4.5 g, every 6 hours)
Study: 8459456
Drug: Gentamicin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (80 mg, every 8 hours) and Metronidazole (500 mg every 6 hours)
Study: 2943309
Drug: Paroxetine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 15 mg
Study: 1836894
Drug: Paroxetine 30
Normalized name: PARoxetine 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 30 mg
Study: 2943309
Drug: Paroxetine 30
Normalized name: PARoxetine 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 30 mg (morning administration)
Study: 20814324
Drug: Nicotine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (8 mg) gum
Study: 10215751
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of recombinant human growth hormone (rhGH)
Study: 16383035
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of isotonic saline (placebo control)
Study: 11896746
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication (Potassium bromide 1X, Sodium bromide 2X, Nickel sulfate 3X, Sodium chloride 6X)
Study: 10554537
Drug: Selenium and
Normalized name: Selenium and/or selenium compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium and vitamin E as antioxidants in addition to standard therapy
Study: 10554537
Drug: Reference group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference group with no additional therapy
Study: 7481869
Drug: Dose-intensive regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-intensive regimen incorporating two courses of carboplatin
Study: 7481869
Drug: High-dose carboplatin/cyclophosphamide/mitoxantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose carboplatin/cyclophosphamide/mitoxantrone
Study: 7481869
Drug: High-dose cisplatin/cyclophosphamide/thiotepa
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin/cyclophosphamide/thiotepa
Study: 7462674
Drug: 0.1% beta‐methasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% beta‐methasone 17‐valerate cream
Study: 7462674
Drug: cream base
Normalized name: Cream Base
Approvals — FDA: no, EMA: no, PMDA: no
Description: cream base
Study: 7462674
Drug: clobetasone butyrate
Normalized name: clobetasone butyrate
Approvals — FDA: no, EMA: no, PMDA: yes
Description: clobetasone butyrate 0.05% cream
Study: 7462674
Drug: hydrocortisone 1%
Normalized name: HYDROCORTISONE 1% OINT
DrugBank: Hydrocortisone acetate (DB14539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydrocortisone 1% cream
Study: 23820460
Drug: Tolvaptan administered
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan administered via nasogastric tube (crushed tablet in suspension)
Study: 23820460
Drug: Tolvaptan tablets
Normalized name: Tolvaptan Tablets
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan tablets swallowed intact (oral administration)
Study: 23204686
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg followed by intravaginal misoprostol 600 μg and 400 μg every 3 hours up to 5 doses
Study: 23204686
Drug: Misoprostol alone
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol alone (600 μg followed by 400 μg every 3 hours up to 5 doses)
Study: 9928923
Drug: Clozapine +
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine + Paroxetine (20 mg)
Study: 9928923
Drug: Clozapine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (2.5 mg/kg)
Study: 2556978
Drug: IgG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG treatment (500 mg/kg, 12 weekly infusions)
Study: 2556978
Drug: IgG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG treatment
Study: 18191528
Drug: Preoperative chemoradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiation therapy (CRT)
Study: 1595998
Drug: Aminophylline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (6 mg/kg loading dose over 20 min, followed by 0.9 mg/kg/h maintenance infusion)
Study: 6372707
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg artificial surfactant in 1 ml saline
Study: 25127011
Drug: Alendronate discontinuation
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate discontinuation (placebo)
Study: 18358540
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) 200 mg/day over 8 weeks
Study: 18358540
Drug: Lithium (Li)
DrugBank: Lithium succinate (DB14508)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (Li) at least 900 mg/day over 2 weeks (serum level 0.6-1.2 mEq/L)
Study: 1710009
Drug: Aprotinin (Trasylol)
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin (Trasylol) high dosage (about 800 mg) during extracorporeal circulation
Study: 7224261
Drug: Cephalexin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin (250 mg orally q.i.d. x 5 days)
Study: 25501100
Drug: OPCAB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPCAB with BMC treatment
Study: 23510529
Drug: Fluoxetine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (10-20 mg/day) plus vitamin C (1000 mg/day)
Study: 23510529
Drug: Fluoxetine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (10-20 mg/day) plus placebo
Study: 21608221
Drug: Weifuchun Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weifuchun Tablet (Control)
Study: 16573982
Drug: No preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preparation (Cohort 1)
Study: 15017515
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid 1.0 g 3 times a day
Study: 15017515
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid 0.5 g 3 times a day
Study: 15017515
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid 1.5 g 3 times a day
Study: 15017515
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (all doses)
Study: 3554818
Drug: Methylphenidate (5
Normalized name: methylphenidate (50/50 release) 20 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (5 to 20 mg/d)
Study: 30274655
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus healthy lifestyle instruction
Study: 26108445
Drug: Topical combination
Normalized name: soap TOPICAL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical combination therapy with maxacalcitol ointment and betamethasone butyrate propionate ointment (BBP)
Study: 26108445
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (BBP) alone
Study: 25187436
Drug: Sodium- and
Normalized name: sodium benzoate and sodium phenylacetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium- and fluid-restricted diet (0.8 g/day sodium and 800 mL/day fluid)
Study: 25187436
Drug: Unrestricted diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unrestricted diet (4 g/day sodium and unlimited fluid intake)
Study: 24097171
Drug: Contrast water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast water therapy (CT)
Study: 15827094
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 25 mg
Study: 15827094
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 50 mg
Study: 15827094
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 125 mg
Study: 15827094
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 300 mg
Study: 15827094
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 600 mg
Study: 18404076
Drug: Continuous beta-blocker
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous beta-blocker (BB)
Study: 15217715
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (in a double-blind, placebo-controlled, randomized clinical trial)
Study: 7810251
Drug: Dexamethasone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (500 mg intravenous infusion within 3 h after trauma, followed by 200 mg after 3 h, then 8 times 200 mg at 6 hourly intervals, total dose 2.3 g in 51 hours)
Study: 26285766
Drug: Iniparib with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iniparib with monthly temozolomide (mTMZ) dosing (150‐200 mg/m(2) days 1‐5/28 days)
Study: 26285766
Drug: Iniparib with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iniparib with continuous temozolomide (cTMZ) dosing (75 mg/m(2)/days × 6 weeks)
Study: 26285766
Drug: Recommended phase
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended phase 2 dosing of iniparib
Study: 18707846
Drug: Infliximab (3mg/kg)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (3mg/kg) administered at baseline
Study: 16939405
Drug: Low-level whole
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level whole body vibration (30 Hz, 0.3g) for 10 minutes daily for 12 months
Study: 16939405
Drug: Low-level whole
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level whole body vibration (30 Hz, 0.3g) for 10 minutes daily for 12 months (per protocol analysis)
Study: 14510790
Drug: Mild laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild laser treatment using an argon green laser
Study: 9108387
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human IL-10 (rhIL-10; 25 microg/kg) pre-treatment
Study: 9108387
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human IL-10 (rhIL-10; 25 microg/kg) post-treatment
Study: 9108387
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human IL-10 (rhIL-10; 25 microg/kg) pre-treatment and post-treatment
Study: 29459150
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1 cartridge of 4% prilocaine plain plus 1 cartridge of 2% lidocaine with 1:100,000 epinephrine
Study: 29459150
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2 cartridges of 2% lidocaine with 1:100,000 epinephrine
Study: 29459150
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 4% prilocaine plain plus 2% lidocaine with 1:100,000 epinephrine
Study: 23131288
Drug: Ulinastatin (UTI)
Normalized name: phenazopyridine hydrochloride Oral Tablet [UTI Relief]
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (UTI) treatment, 200 kU every 8 hours
Study: 20367218
Drug: 40 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g/day palatinose-blended sugar (PS group)
Study: 20367218
Drug: 40 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g/day sucrose (S group)
Study: 15983450
Drug: 30% inspired
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% inspired oxygen in air plus intravenous administration of saline
Study: 15983450
Drug: 80% inspired
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80% inspired oxygen in air plus intravenous administration of saline
Study: 10372238
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg fenfluramine three times a day and 37.5 mg phentermine daily (n = 23)
Study: 9092419
Drug: Aspirin (100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100-300 mg/day)
Study: 9092419
Drug: Aspirin (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (for primary prevention)
Study: 1931470
Drug: Magnesium hydroxide
Normalized name: Magnesium Hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium hydroxide (850 mg) with non-micronised glibenclamide (2.5 mg)
Study: 1931470
Drug: Magnesium hydroxide
Normalized name: Magnesium Hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium hydroxide (850 mg) with micronised glibenclamide (1.75 mg)
Study: 1931470
Drug: Water only
Normalized name: Water only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water only (150 ml) with micronised glibenclamide (1.75 mg)
Study: 1931470
Drug: Water only
Normalized name: Water only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water only (150 ml) with non-micronised glibenclamide (2.5 mg)
Study: 6799077
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg four times a day
Study: 3610515
Drug: Topical benzydamine
Normalized name: benzydamine Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzydamine
Study: 1774006
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac
Study: 25128052
Drug: Hospital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital treatment as usual (7 days)
Study: 25128052
Drug: Early assisted
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early assisted discharge (3 days in hospital followed by treatment at home)
Study: 22054782
Drug: Losartan/HCTZ combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan/HCTZ combination therapy
Study: 22054782
Drug: High-dose amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose amlodipine monotherapy
Study: 18949456
Drug: Conventional regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional regimens (n = 109) of propofol, midazolam or lorazepam combined with fentanyl or morphine.
Study: 17125957
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (n = 21)
Study: 16372801
Drug: Hydrocortisone (cream)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (cream)
Study: 16372801
Drug: Hydrocortisone (ointment)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (ointment)
Study: 16372801
Drug: Hydrocortisone butyrate
Normalized name: Hydrocortisone Butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone butyrate (cream)
Study: 16372801
Drug: Hydrocortisone butyrate
Normalized name: Hydrocortisone Butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone butyrate (ointment)
Study: 16372801
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (cream)
Study: 16372801
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (ointment)
Study: 10868615
Drug: Single-dose miconazole
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose miconazole nitrate (1200 mg) vaginal ovule
Study: 10868615
Drug: Monistat 7
Normalized name: Monistat 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monistat 7 (miconazole nitrate 2%) Vaginal Cream
Study: 1425900
Drug: Piroxicam suppository
Normalized name: piroxicam Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam suppository (20 mg)
Study: 30986738
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive behavioral therapy (n = 76)
Study: 30071980
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (n = 76)
Study: 30348185
Drug: GMCT (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMCT (800 mg daily)
Study: 22840413
Drug: Transversus abdominis
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transversus abdominis plane (TAP) block with 20 mL of 0.5% ropivacaine with epinephrine 1:200,000
Study: 18230831
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) 500 mg administered intravenously over three consecutive days, in four cycles at 4 weekly intervals (total 6 g of MP).
Study: 18230831
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) administered intravenously over three consecutive days, in four cycles at 4 weekly intervals.
Study: 15851425
Drug: Gaviscon Infant
Normalized name: Gaviscon
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaviscon Infant (625 mg in 225 ml milk)
Study: 15851425
Drug: Placebo (mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mannitol and Solvito N, 625 mg in 225 ml milk)
Study: 15320475
Drug: Endothelin receptor
Normalized name: Endothelin receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin receptor antagonists (selective ET-A and non-selective ET-A/B receptor antagonists)
Study: 15320475
Drug: Investigational drugs
Normalized name: INVESTIGATIONAL DRUGS FOR DEMENTIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drugs targeting endothelin system
Study: 10400482
Drug: 64 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64 mg/day beta-carotene for 1 week
Study: 1810525
Drug: Meclofenamate sodium
Normalized name: Meclofenamate Sodium
DrugBank: Meclofenamic acid (DB00939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meclofenamate sodium (100 mg)
Study: 1806546
Drug: Piroxicam-beta-cyclodextrin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam-beta-cyclodextrin (20 mg)
Study: 22709952
Drug: Seasonal inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal inactivated trivalent influenza vaccine (TIV)
Study: 15089813
Drug: Quinidine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (600 mg)
Study: 1951002
Drug: Mexiletine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (400 mg)
Study: 7096998
Drug: Human diploid
Normalized name: rabies vaccine, human diploid cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human diploid cell rabies vaccine, administered in 0.1 ml volumes intradermally (i.d.) or as 1.0 ml intramuscularly (i.m.)
Study: 7096998
Drug: Three injections
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three injections of human diploid cell rabies vaccine
Study: 7096998
Drug: Booster doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster doses administered by the subcutaneous (s.c.) or i.d. route
Study: 7096998
Drug: Intradermal (i.d.)
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (i.d.) immunization